Seaport Therapeutics, Inc. 8-K

What Happened

• Seaport Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 in a press release dated June 8, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed on June 8, 2026. The filing clarifies the exhibit is being furnished (not “filed”) under the Exchange Act.

Key Details

• Date of announcement: June 8, 2026.
• Period reported: three months ended March 31, 2026 (quarterly results / earnings).
• Press release provided as Exhibit 99.1 to the Form 8-K.
• Report signed on behalf of the company by Lauren White, Chief Financial Officer (Principal Financial and Accounting Officer).

Why It Matters

• This filing signals Seaport has issued its latest quarterly financial results and related commentary; investors should review the furnished press release (Exhibit 99.1) for revenue, earnings, cash position, and operational updates.
• Because the information is furnished rather than filed, it is made public for disclosure but is not subject to certain Exchange Act liabilities or automatically incorporated by reference into future filings.